Učitavanje...
Bevacizumab-Based Treatment in Colorectal Cancer with a NRAS Q61K Mutation
Despite development of new therapies, metastatic colorectal cancer (mCRC) largely remains an incurable disease. Approximately 2–6% of colorectal cancers harbor NRAS mutations. The anti-VEGF antibody bevacizumab is a backbone of most therapeutic regimens; however, biomarkers predicting its activity a...
Spremljeno u:
| Glavni autori: | , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2013
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3766504/ https://ncbi.nlm.nih.gov/pubmed/23400451 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11523-013-0266-9 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|